127 related articles for article (PubMed ID: 38018850)
1. Clinical Guidance for Dosing and Monitoring Oral Antihormonal Drugs in Patients with Breast Cancer After Roux-en-Y Gastric Bypass.
Kingma JS; Peeters NWL; Knibbe CAJ; Agterof MJ; Derksen WJM; Burgers DMT; van den Broek MPH
Ther Drug Monit; 2024 Jun; 46(3):404-409. PubMed ID: 38018850
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature.
Wills SM; Zekman R; Bestul D; Kuwajerwala N; Decker D
Pharmacotherapy; 2010 Feb; 30(2):217. PubMed ID: 20099995
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.
Groenland SL; van Nuland M; Verheijen RB; Schellens JHM; Beijnen JH; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2019 Mar; 58(3):299-308. PubMed ID: 29862467
[TBL] [Abstract][Full Text] [Related]
4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
6. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
7. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Plummer R; Verheul HM; De Vos FYFL; Leunen K; Molife LR; Rolfo C; Grundtvig-Sørensen P; De Grève J; Rottey S; Jerusalem G; Italiano A; Spicer J; Dirix L; Goessl C; Birkett J; Spencer S; Learoyd M; Bailey C; Dean E
Adv Ther; 2018 Nov; 35(11):1945-1964. PubMed ID: 30324586
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
11. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
13. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
[TBL] [Abstract][Full Text] [Related]
14. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
15. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant endocrine therapy in breast cancer.
Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
19. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
